Your search for non small cell lung cancer returned 51 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Da Hee Han, PharmD remove

Your search for non small cell lung cancer returned 51 results

Sort Results:

Relevant Recent
News

Keytruda Gains Expanded Monotherapy Indication for First-Line Treatment of NSCLC

Merck announced that the Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 (tumor proportion score [TPS] ≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
News

Tagrisso Approved as First-Line Treatment for EGFR-Mutated NSCLC

Results showed that progression-free survival (PFS), the primary endpoint, was significantly longer in Tagrisso-treated patients vs EGFR tyrosine kinase inhibitor-treated patients (18.9 months vs 10.2 months; hazard ratio [HR] 0.46, 95% CI: 0.37, 0.57; P <.0001).